Business Context and Reporting Period
Company: Ocular Therapeutix, Inc.
Filing Type: Form 8-K (Current Report)
Date: April 28, 2020
Event: Announcement of topline results from a Phase 3 clinical trial for DEXTENZA.
Key Financial Metrics
This filing is a Current Report (Item 8.01) regarding a clinical trial update. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metric.
Material Changes and Clinical Results
The Company reported positive topline results from a Phase 3 randomized, double-masked, placebo-controlled trial evaluating DEXTENZA for ocular itching associated with allergic conjunctivitis.
- Study Design: 96 subjects enrolled across 6 U.S. sites using the Ora-Cac Model.
- Primary Endpoint: Ocular itching on Day 8 (afternoon) at 3, 5, and 7 minutes post-challenge.
- Results: DEXTENZA demonstrated a statistically significant reduction in itching compared to vehicle (p-value < 0.0001) at all three time points.
- Secondary Endpoints: Lower itching scores observed at 20 of 21 additional time points (p-value < 0.05).
- Safety: Favorable profile with no serious adverse events, no rescue medication required, and no elevated intraocular pressure. 8 total ocular treatment emergent adverse events occurred (2 in DEXTENZA group, 6 in vehicle group).
Outlook and Management Commentary
Management intends to request a meeting with the FDA to discuss the potential submission in 2020 of a supplement to the existing New Drug Application (NDA) for DEXTENZA. The goal is to include the treatment of ocular itching associated with allergic conjunctivitis as an additional approved indication. The Company is continuing to assess additional secondary endpoints.
Investor Verification Checklist
- Verify the FDA meeting date and outcome regarding the NDA supplement for allergic conjunctivitis.
- Monitor the full clinical study report for detailed safety data and secondary endpoint analysis.
- Assess the potential market size and competitive landscape for DEXTENZA in the allergic conjunctivitis indication.
- Review upcoming quarterly financial reports for cash burn rate and runway, as this 8-K contains no financial data.